The Gabelli Healthcare & Wellness Trust, a diversified investment fund focused on long-term capital growth, saw healthcare stocks underperform the broader market in April and May. However, the sector rebounded strongly in June, helped by a decline in technology and AI stocks which shifted investor focus back to healthcare. Managed care companies were the most consistent performers during the quarter, driving the sector's recovery. This rebound highlights shifting market dynamics and potential opportunities in healthcare investments going forward.
The Gabelli Healthcare & WellnessRX Trust commentary provides context for healthcare sector performance. For readers following healthcare stocks, here is Pluang's market snapshot as of Sep 22, 2026 19:02 WIB: Of 101 priced health-sector US stocks tradable on Pluang, 50 rose and 41 fell today. Notable movers include Alcon AG (ALC) at USD 65.57 with a 1-day change of +1.08%, Cassava Sciences Inc (FLNA) at USD 0.73 with -1.04%, and Revvity Inc (RVTY) at USD 144.98 with +0.97%.
Abivax received positive pre-NDA feedback from the U.S. FDA for its drug Obefazimod, marking a key step in its development. Despite a recent price target cut by Wedbush to $118, analysts maintain a "Moderate Buy" consensus with an average target of $...
HSBC and Wells Fargo have downgraded Netflix stock due to declining subscriber engagement and an 8% drop in viewership time. Despite a recent 2.19% stock gain, Netflix shares have fallen over 40% in the past year amid strong competition and weaker or...
Smiths Group reported solid fiscal 2026 results, meeting EPS and revenue expectations with an EPS of $0.66 and revenue of $1.37 billion. The company improved operating profit, driven by strategic portfolio changes including selling non-core divisions...
Cintas Corporation is set to report its Q3 earnings with an expected EPS of $1.35 and revenue of $2.98 billion, up from $2.72 billion last year. The growth is supported by strong customer retention, increased demand for services like AED Rentals, and...
An analyst from Barclays has lowered Constellation Brands' stock price target to $122, slightly above its current trading price near a 52-week low. The company is refining its beer portfolio strategy with brand-specific plans and supply-chain improve...
